CMCase produced by a novel Bacillus subtilis strain Fatma/1 degraded bacterial biofilms of some nosocomial pathogens in vitro
Microbial Biotechnology Department, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, 22857, Menoufia Governorate, Egypt.
Research Article
Open Access Research Journal of Medical and Clinical Case Reports, 2021, 01(02), 001–008.
Article DOI: 10.53022/oarjmccr.2021.1.2.0023
Publication history:
Received on 24 July; revised on 23 September 2021; accepted on 25 September 2021
Abstract:
Nosocomial bacteria's ability to produce biofilms helps them survive in a variety of environments, such as hospitals, wounds, and medical devices. Cellulases can destroy cellulose, one of the major structural components of biofilms, representing an important part of the bacterial biofilm matrix.
Bacterial strains were obtained from diabetic foot hospital patients and tested for their ability to produce biofilms in vitro. Isolates were identified as Staphylococcus aureus, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli using a standard set of biochemical assays commonly used at hospital laboratory. Biofilm degradation by CMCase enzyme was evaluated through in vitro tube method, microscopic observation and crystal violet assay.
CMCase had a high effectiveness in eliminating P. aeruginosa biofilms and a modest capacity to remove biofilms of other strains used in this study. Light microscopy demonstrated fully disseminated cells of P. aeruginosa biofilm exposed to CMCase. Besides, Using CMCase dramatically eliminated 87.5% of the carbohydrate content of its biofilm matrix.
Keywords:
CMCase; Bacterial biofilm; Pseudomonas aeruginosa; Bacillus subtilis; Nosocomial infections.
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0